198 related articles for article (PubMed ID: 37795639)
1. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
[TBL] [Abstract][Full Text] [Related]
2. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
[TBL] [Abstract][Full Text] [Related]
3. Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice.
Gabe MBN; von Voss L; Hunt JE; Gadgaard S; Gasbjerg LS; Holst JJ; Kissow H; Hartmann B; Rosenkilde MM
Br J Pharmacol; 2023 Jul; 180(13):1674-1689. PubMed ID: 36683195
[TBL] [Abstract][Full Text] [Related]
4. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
5. The role of G protein-coupled receptor kinases in GLP-1R β-arrestin recruitment and internalisation.
McNeill SM; Lu J; Marion C Carino C; Inoue A; Zhao P; Sexton PM; Wootten D
Biochem Pharmacol; 2024 Apr; 222():116119. PubMed ID: 38461904
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist.
Jones B; Burade V; Akalestou E; Manchanda Y; Ramchunder Z; Carrat G; Nguyen-Tu MS; Marchetti P; Piemonti L; Leclerc I; Thennati R; Vilsboll T; Thorens B; Tomas A; Rutter GA
Diabetes Obes Metab; 2022 Nov; 24(11):2090-2101. PubMed ID: 35676825
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
Marzook A; Chen S; Pickford P; Lucey M; Wang Y; Corrêa IR; Broichhagen J; Hodson DJ; Salem V; Rutter GA; Tan TM; Bloom SR; Tomas A; Jones B
Biochem Pharmacol; 2021 Aug; 190():114656. PubMed ID: 34129856
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
11. Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeutics.
El Eid L; Reynolds CA; Tomas A; Ben Jones
Pharmacol Res; 2022 Oct; 184():106411. PubMed ID: 36007775
[TBL] [Abstract][Full Text] [Related]
12. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
13. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists.
Lucey M; Pickford P; Bitsi S; Minnion J; Ungewiss J; Schoeneberg K; Rutter GA; Bloom SR; Tomas A; Jones B
Mol Metab; 2020 Jul; 37():100991. PubMed ID: 32278079
[TBL] [Abstract][Full Text] [Related]
14. Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome.
Hao Y; Wei M; Zhang N; Zhang X
Bioengineered; 2022 Mar; 13(3):5467-5479. PubMed ID: 35184645
[TBL] [Abstract][Full Text] [Related]
15. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
16. Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.
Yang Q; Zhou F; Tang X; Wang J; Feng H; Jiang W; Jin L; Jiang N; Yuan Y; Han J; Yan Z
Eur J Med Chem; 2022 Apr; 233():114214. PubMed ID: 35231829
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.
Fletcher MM; Halls ML; Zhao P; Clydesdale L; Christopoulos A; Sexton PM; Wootten D
Biochem Pharmacol; 2018 Oct; 156():406-419. PubMed ID: 30195733
[TBL] [Abstract][Full Text] [Related]
18. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
[TBL] [Abstract][Full Text] [Related]
19. β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.
Hager MV; Johnson LM; Wootten D; Sexton PM; Gellman SH
J Am Chem Soc; 2016 Nov; 138(45):14970-14979. PubMed ID: 27813409
[TBL] [Abstract][Full Text] [Related]
20. Divergent acute versus prolonged pharmacological GLP-1R responses in adult β cell-specific β-arrestin 2 knockout mice.
Bitsi S; El Eid L; Manchanda Y; Oqua AI; Mohamed N; Hansen B; Suba K; Rutter GA; Salem V; Jones B; Tomas A
Sci Adv; 2023 May; 9(18):eadf7737. PubMed ID: 37134170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
